Financial Challenges of Long-Term Cancer Medications
Author Information
Author(s): Elshiekh Cleopatra, Rudà Roberta, Cliff Edward R, Gany Francesca, Budhu Joshua A
Primary Institution: Memorial Sloan Kettering Cancer Center
Hypothesis
How do high costs of long-term targeted therapies impact patients with IDH-mutant gliomas?
Conclusion
The high costs of targeted cancer therapies can lead to financial toxicity, affecting patient adherence and quality of life.
Supporting Evidence
- High costs of targeted cancer therapies often exceed $150,000 annually.
- Financial toxicity can lead to medical debt, income loss, and psychological stress.
- Many cancer patients face substantial out-of-pocket expenses and potential treatment abandonment.
Takeaway
Some cancer medicines are really expensive, and that can make it hard for patients to pay for them, which might stop them from getting the help they need.
Methodology
This review analyzes drug approval and pricing mechanisms in various countries and their impact on healthcare costs and patient access.
Potential Biases
Potential bias in the analysis due to the focus on high-cost medications without considering lower-cost alternatives.
Limitations
The review does not provide specific data on patient outcomes or adherence rates.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website